Overview

Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain

Status:
NOT_YET_RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension
Phase:
PHASE3
Details
Lead Sponsor:
Hope Medicine (Nanjing) Co., Ltd